product name Rocuronium Bromide
Description: Rocuronium Bromide (also known as ORG 9426) is a competitive AchR antagonist, which is used in modern anaesthesia. Rocuronium bromide, an aminosteroid type neuromuscular blocking agent, acts by reducing or inhibiting the depolarising effect of acetylcholine on the terminal disc of the muscle cell. Rocuronium interacts with human liver microsomal cytochromes P450 (CYP) by binding to the substrate site. Rocuronium has caused inhibition of both reactions by 20 and 15%, respectively.
References: Cytotechnology. 2011 May;63(3):239-45; Vet Ophthalmol. 2011 Jul;14(4):244-7.
609.68
Formula
C32H53N2O4.Br
CAS No.
119302-91-9
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 122 mg/mL (200.1 mM)
Water: 122 mg/mL (200.1 mM)
Ethanol: 122 mg/mL (200.1 mM)
Solubility (In vivo)
Synonyms
ORG 9426
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19390700
| In Vitro |
In vitro activity: Rocuronium bromide (RB), an aminosteroid type neuromuscular blocking agent, acts by reducing or inhibiting the depolarising effect of acetylcholine on the terminal disc of the muscle cell. Rocuronium interacts with human liver microsomal cytochromes P450 (CYP) by binding to the substrate site. Rocuronium has caused inhibition of both reactions by 20 and 15%, respectively. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Rocuronium is an ideal muscle relaxant with a rapid onset, intermediate duration of action, nondepolarizing properties and lack of cardiovascular side effects. Rocuronium produces a dose-dependent duration of neuromuscular blockade in isoflurane anesthetized horses. Rocuronium bromide, is a relatively low potency, intermediate-acting agent with a rapid onset time of 98 seconds in dogs. Rocuronium is an effective nondepolarizing muscle relaxant in the cat under the clinical conditions of this study. Rocuronium has a rapid onset, a short duration of action. Rocuronium (0.6 mg/kg) results in a significant increase in heart rate one min after IV administration in the dog. Rocuronium (0.3 mg/kg and 0.6 mg/kg) produce a reliable neuromuscular block of 23–32 min duration, respectively. Rocuronium bromide paralyzes the internal laryngeal muscles keeping the vocal cords in an intermediate position (paramedial) 60 seconds after being administered in cats. |
| Animal model | |
| Formulation & Dosage | |
| References | Cytotechnology. 2011 May;63(3):239-45; Vet Ophthalmol. 2011 Jul;14(4):244-7. |
Related Posts
product name Rocuronium Bromide
Description: Rocuronium Bromide (also known as ORG 9426) is a competitive AchR antagonist, which is used in modern anaesthesia. Rocuronium bromide, an aminosteroid type neuromuscular blocking agent, acts by reducing or inhibiting the depolarising effect of acetylcholine on the terminal disc of the muscle cell. Rocuronium interacts with human liver microsomal cytochromes P450 (CYP) by binding to the substrate site. Rocuronium has caused inhibition of both reactions by 20 and 15%, respectively.
References: Cytotechnology. 2011 May;63(3):239-45; Vet Ophthalmol. 2011 Jul;14(4):244-7.
609.68
Formula
C32H53N2O4.Br
CAS No.
119302-91-9
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 122 mg/mL (200.1 mM)
Water: 122 mg/mL (200.1 mM)
Ethanol: 122 mg/mL (200.1 mM)
Solubility (In vivo)
Synonyms
ORG 9426
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19390700
| In Vitro |
In vitro activity: Rocuronium bromide (RB), an aminosteroid type neuromuscular blocking agent, acts by reducing or inhibiting the depolarising effect of acetylcholine on the terminal disc of the muscle cell. Rocuronium interacts with human liver microsomal cytochromes P450 (CYP) by binding to the substrate site. Rocuronium has caused inhibition of both reactions by 20 and 15%, respectively. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Rocuronium is an ideal muscle relaxant with a rapid onset, intermediate duration of action, nondepolarizing properties and lack of cardiovascular side effects. Rocuronium produces a dose-dependent duration of neuromuscular blockade in isoflurane anesthetized horses. Rocuronium bromide, is a relatively low potency, intermediate-acting agent with a rapid onset time of 98 seconds in dogs. Rocuronium is an effective nondepolarizing muscle relaxant in the cat under the clinical conditions of this study. Rocuronium has a rapid onset, a short duration of action. Rocuronium (0.6 mg/kg) results in a significant increase in heart rate one min after IV administration in the dog. Rocuronium (0.3 mg/kg and 0.6 mg/kg) produce a reliable neuromuscular block of 23–32 min duration, respectively. Rocuronium bromide paralyzes the internal laryngeal muscles keeping the vocal cords in an intermediate position (paramedial) 60 seconds after being administered in cats. |
| Animal model | |
| Formulation & Dosage | |
| References | Cytotechnology. 2011 May;63(3):239-45; Vet Ophthalmol. 2011 Jul;14(4):244-7. |